PDF(Pubmed)
Abstract：
The presence of tertiary lymphoid structures (TLSs) associated with distinct treatment efficacy and clinical prognosis has been identified in various cancer types. However, the mechanistic roles and clinical implications of TLSs in genitourinary (GU) cancers remain incompletely explored. Despite their potential role as predictive markers described in numerous studies, it is essential to comprehensively evaluate the characteristics of TLSs, including drivers of formation, structural foundation, cellular compositions, maturation stages, molecular features, and specific functionality to maximize their positive impacts on tumor-specific immunity. The unique contributions of these structures to cancer progression and biology have fueled interest in these structures as mediators of antitumor immunity. Emerging data are trying to explore the effects of therapeutic interventions targeting TLSs. Therefore, a better understanding of the molecular and phenotypic heterogeneity of TLSs may facilitate the development of TLSs-targeting therapeutic strategies to obtain optimal clinical benefits for GU cancers in the setting of immunotherapy. In this review, the authors focus on the phenotypic and functional heterogeneity of TLSs in cancer progression, current therapeutic interventions targeting TLSs and the clinical implications and therapeutic potential of TLSs in GU cancers.
摘要：
已在各种癌症类型中确定了与不同的治疗功效和临床预后相关的三级淋巴结构（TLSs）的存在。然而,TLS在泌尿生殖系统（GU）癌症中的机制作用和临床意义仍未完全探索。尽管在许多研究中描述了它们作为预测标志物的潜在作用，全面评估TLS的特点至关重要，包括编队的驱动因素，结构基础,细胞成分，成熟阶段,分子特征，和特定功能，以最大限度地发挥其对肿瘤特异性免疫的积极影响。这些结构对癌症进展和生物学的独特贡献激发了人们对这些结构作为抗肿瘤免疫介质的兴趣。新兴数据试图探索针对TLS的治疗干预措施的效果。因此,更好地了解TLS的分子和表型异质性,可能有助于开发靶向TLS的治疗策略,从而在免疫治疗环境中获得最佳的GU癌症临床获益.在这次审查中,我们关注癌症进展中TLS的表型和功能异质性，当前针对TLS的治疗干预以及TLS在GU癌症中的临床意义和治疗潜力。
